Coronavirus (COVID-19) outbreak: How you can get help.

 

We’re making changes to our website. Your feedback will help us improve it.

  1. Home
  2. News and stories
  3. A clinical trial of a new investigational drug for vertigo in Ménière’s disease – OTO-104

A clinical trial of a new investigational drug for vertigo in Ménière’s disease – OTO-104

A clinical study team are looking for volunteers to test their new investigational drug, OTO-104, for vertigo episodes in Ménière’s disease.

By the OTO-104 Study Team

What is a clinical trial?

Clinical trials help scientists and doctors explore whether a medical strategy, treatment, or device is safe and effective for humans. Information obtained during this trial may be useful scientifically and therefore may be helpful to people with Ménière’s disease in the future. It is not known if the Investigational Product (IP) or placebo will help your condition.

The purpose of the trial

The purpose of this trial is to determine the safety and effectiveness of the investigational product on vertigo episodes (spinning feeling) in patients with Ménière’s disease.

Why you should participate

Your participation in this trial may help researchers learn more about Ménière’s disease and potentially find a treatment option for patients with Ménière’s disease in the future.

Ménière’s disease is a disorder of the inner ear that causes episodes in which you feel like you are spinning (vertigo) and have fluctuating hearing loss, ringing in the ear (tinnitus), and ear fullness or pressure. The cause of Ménière’s disease is not fully understood, but one popular theory is that Ménière’s disease is the result of an abnormal amount of fluid in the inner ear. Currently, there is no cure for the disease. Available treatment tends to focus on relieving the vertigo symptoms, but these treatments can be ineffective. It is important that researchers continue to trial more effective alternatives for Ménière’s disease.

Who can join

You may be able to join the trial if you meet these criteria (other criteria will also apply):

  • 18 to 85 years of age
  • Have been diagnosed with Ménière’s disease in one ear
  • Have had spinning (vertigo) episodes for 2 months before joining the trial.

The investigational product

The investigational product is given as a single injection into the middle ear through the eardrum. It is considered “investigational” because it has not been approved by the United States Food and Drug Administration (FDA) or another regulatory authority for treating Ménière’s disease. The investigational product is being developed in hopes that it may relieve vertigo symptoms.

This active investigational product will be compared to placebo, which is also given as an injection, but it has no active ingredients.

What trial participants can expect

If you are eligible and agree to join the trial, your participation will last about 16 weeks, including a 4-week lead-in period and a 12-week follow-up period.

  • During the lead-in period, you will record your daily vertigo experiences by telephone in a trial diary.
  • If you complete your diary entries during the lead-in period and qualify to participate, you will be randomly assigned (like by the flip of a coin), with a 50/50 chance, to receive either a single injection of the active Investigational Product or placebo.
  • After your injection, you will continue to record your daily vertigo experiences. You will visit the trial clinic at Weeks 4 and 8, and you will receive assessments to measure the effectiveness and monitor the safety of the Investigational Product or placebo. You will have a final visit at Week 12.

Where and when it is taking place

The study is underway now and is taking place at the following clinical research centres and hospitals in the UK:

Angus

Ninewells Hospital and Medical School
Dundee, Angus, DD1 9SY
Contact: P Spielmann, 01382 633899, patrickspielmann@nhs.net

Belfast

Royal Victoria Hospital, Belfast BT12 6BA
Contact: Neil Bailie, neila.bailie@belfasttrust.hscni.net

Cambridge

Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ
Contact: Neil Donnelly, 01223 586638, neil.donnelly@addenbrookes.nhs.uk

Cardiff

University Hospital of Wales, Cardiff CF14 4XW
Contact: Julia Dolby, 02920 743174, julia.dolby@wales.nhs.uk

Gloucester

Gloucestershire Royal Hospital, Gloucester GL1 3NN
Contact: Matthew Clark, matthew.clark11@nhs.net

Leicester

University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester LE1 5WW
Contact: Adam Lewszuk, 01162 585973, clinical.research@uhl-tr.nhs.uk

London

Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT
Contact: Abigail Tetteh, ENTResearch@gstt.nhs.uk

Manchester

Manchester Head and Neck Centre, Peter Mount Building, Manchester M13 9WL
Contact: Alice Panes, 01617 011262, alice.panes@mft.nhs.uk

Norwich

Norfolk & Norwich University Hospital, Norwich NR4 7UY
Contact: Catherine Wright, 01603 64 6108, catherine.wright@nnuh.nhs.uk

Sheffield

The Royal Hallamshire Hospital, Sheffield S10 2JF
Contact: Jayne Wilson, 01142 71339, jayne.willson@sth.nhs.uk

Further information

If you are interested in taking part in the study and would like to receive further information, please contact the hospital or research centre noted above that’s located closest to you.

To find out more about clinical trials, please visit the National Institute for Health Research website.

More like this